RBC Capital analyst Shagun Singh has just launched coverage on DexCom (NASDAQ: DXCM) with an optimistic rating and a target price of $165. This news indicates a bright future for the company. Dexcom, a leading provider of continuous glucose monitoring (CGM) systems, has recently unveiled a groundbreaking over-the-counter CGM named Stelo. This innovative product has received FDA clearance for non-prescription use, targeting Type 2 diabetes patients who do not require insulin. Stelo is the first glucose biosensor that can be purchased without a prescription, set to hit online shelves in the summer of 2024. This advancement aims to broaden CGM accessibility by allowing individuals to buy a CGM independently, eliminating the need for healthcare provider involvement. This will greatly benefit patients without insurance coverage for CGMs, opening up new possibilities for managing their health.
DexCom Inc. (DXCM) Stock Sees Slight Decrease, But Positive Pre-Market Activity Indicates Potential for Gains
On March 12, 2024, DexCom Inc. (DXCM) saw a slight decrease in its stock price, with shares falling by $2.21 or 1.63% from the previous market close of $133.04. Despite this drop, DXCM is still trading near the top of its 52-week range and above its 200-day simple moving average, indicating a strong performance overall.
In pre-market trading, DXCM shares have since risen by $0.00, suggesting that investors may be optimistic about the stock’s potential for the day ahead. Investors should keep an eye on DXCM stock throughout the day to see how it performs in the market. With its strong price momentum and positive pre-market trading activity, the stock may continue to see gains in the near future.
DexCom Inc. (DXCM) Reports Strong Financial Performance with 24.49% Increase in Total Revenue
On March 12, 2024, DexCom Inc. (DXCM) saw a positive performance in terms of its financials, as reported by CNN Money. The total revenue for the company was $3.62 billion for the past year, showing a 24.49% increase compared to the previous year. The net income for DexCom Inc. was $541.50 million for the past year, which marks a significant 58.7% increase from the previous year. Earnings per share (EPS) for DexCom Inc. were $1.30 for the past year, showing a 63.16% increase from the previous year. Overall, DexCom Inc. showed strong financial performance with significant increases in total revenue and net income over the past year. Investors and analysts may view these financial results as a sign of growth and stability for DexCom Inc., which could potentially lead to an increase in the company’s stock price.
